Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:HIMS NASDAQ:RXRX NASDAQ:SDGR NASDAQ:SMMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHIMSHims & Hers Health$24.23+0.4%$23.62$13.74▼$70.43$5.50B2.4335.81 million shs18.24 million shsRXRXRecursion Pharmaceuticals$3.04-0.3%$3.35$2.80▼$7.18$1.62B1.0512.52 million shs14.86 million shsSDGRSchrodinger$12.62-1.0%$12.14$10.94▼$27.63$941.27M1.571.62 million shs1.06 million shsSMMTSummit Therapeutics$18.14-3.5%$18.78$13.83▼$30.98$14.58B-1.255.35 million shs1.97 million shs10 Best Stocks to Own in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHIMSHims & Hers Health+0.52%-5.62%+13.29%+48.55%-60.80%RXRXRecursion Pharmaceuticals-0.33%-7.03%-14.12%-12.89%-29.47%SDGRSchrodinger-1.02%-4.97%+5.96%+10.70%-47.24%SMMTSummit Therapeutics-3.46%+5.77%-13.00%+21.26%-20.26%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHIMSHims & Hers Health$24.23+0.4%$23.62$13.74▼$70.43$5.50B2.4335.81 million shs18.24 million shsRXRXRecursion Pharmaceuticals$3.04-0.3%$3.35$2.80▼$7.18$1.62B1.0512.52 million shs14.86 million shsSDGRSchrodinger$12.62-1.0%$12.14$10.94▼$27.63$941.27M1.571.62 million shs1.06 million shsSMMTSummit Therapeutics$18.14-3.5%$18.78$13.83▼$30.98$14.58B-1.255.35 million shs1.97 million shs10 Best Stocks to Own in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHIMSHims & Hers Health+0.52%-5.62%+13.29%+48.55%-60.80%RXRXRecursion Pharmaceuticals-0.33%-7.03%-14.12%-12.89%-29.47%SDGRSchrodinger-1.02%-4.97%+5.96%+10.70%-47.24%SMMTSummit Therapeutics-3.46%+5.77%-13.00%+21.26%-20.26%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHIMSHims & Hers Health 2.12Hold$29.5021.73% UpsideRXRXRecursion Pharmaceuticals 2.20Hold$8.10166.45% UpsideSDGRSchrodinger 2.33Hold$20.2560.46% UpsideSMMTSummit Therapeutics 2.50Moderate Buy$27.5852.06% UpsideCurrent Analyst Ratings BreakdownLatest SMMT, SDGR, RXRX, and HIMS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2026RXRXRecursion Pharmaceuticals Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$5.00 ➝ $5.505/14/2026SDGRSchrodinger Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$19.00 ➝ $17.005/13/2026HIMSHims & Hers Health Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$32.00 ➝ $30.005/12/2026HIMSHims & Hers Health Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Sell (D)5/12/2026HIMSHims & Hers Health Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$24.505/12/2026HIMSHims & Hers Health UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$35.005/12/2026HIMSHims & Hers Health Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$32.005/12/2026HIMSHims & Hers Health CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$24.00 ➝ $28.005/12/2026HIMSHims & Hers Health JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$35.00 ➝ $33.005/12/2026HIMSHims & Hers Health Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$30.00 ➝ $35.005/12/2026HIMSHims & Hers Health BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHIMSHims & Hers Health$2.37B2.33$0.84 per share28.84$1.96 per share12.36RXRXRecursion Pharmaceuticals$65.74M24.50N/AN/A$1.93 per share1.58SDGRSchrodinger$255.87M3.64N/AN/A$4.25 per share2.97SMMTSummit TherapeuticsN/AN/AN/AN/A$0.70 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHIMSHims & Hers Health$128.37M-$0.09N/A49.4621.62-0.56%6.10%1.52%N/ARXRXRecursion Pharmaceuticals-$644.76M-$1.20N/AN/AN/A-842.95%-54.33%-40.60%N/ASDGRSchrodinger-$103.26M-$1.41N/AN/AN/A-40.61%-30.85%-15.32%N/ASMMTSummit Therapeutics-$1.08B-$1.60N/AN/AN/AN/A-291.24%-243.07%N/ALatest SMMT, SDGR, RXRX, and HIMS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026HIMSHims & Hers Health$0.04-$0.40-$0.44-$0.40$616.84 million$608.10 million5/6/2026Q1 2026RXRXRecursion Pharmaceuticals-$0.30-$0.22+$0.08-$0.22$15.78 million$6.47 million5/5/2026Q1 2026SDGRSchrodinger-$0.56-$0.81-$0.25-$0.81$47.57 million$58.59 million4/30/2026Q1 2026SMMTSummit Therapeutics-$0.2692-$0.24+$0.0292-$0.24$0.05 millionN/A2/25/2026Q4 2025RXRXRecursion Pharmaceuticals-$0.28-$0.21+$0.07-$0.21$24.56 million$35.54 million2/25/2026Q4 2025SDGRSchrodinger-$0.13$0.44+$0.57$0.44$83.66 million$87.24 million2/23/2026Q4 2025HIMSHims & Hers Health$0.02$0.08+$0.06$0.08$619.48 million$617.82 million2/23/2026Q4 2025SMMTSummit Therapeutics-$0.22-$0.29-$0.07-$0.29$75.47 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthHIMSHims & Hers HealthN/AN/AN/AN/AN/ARXRXRecursion PharmaceuticalsN/AN/AN/AN/AN/ASDGRSchrodingerN/AN/AN/AN/AN/ASMMTSummit TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHIMSHims & Hers Health2.181.691.70RXRXRecursion Pharmaceuticals0.015.475.47SDGRSchrodingerN/A2.742.74SMMTSummit TherapeuticsN/A7.417.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHIMSHims & Hers Health63.52%RXRXRecursion Pharmaceuticals89.06%SDGRSchrodinger79.05%SMMTSummit Therapeutics4.61%Insider OwnershipCompanyInsider OwnershipHIMSHims & Hers Health11.76%RXRXRecursion Pharmaceuticals8.43%SDGRSchrodinger10.10%SMMTSummit Therapeutics83.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHIMSHims & Hers Health2,442227.94 million201.13 millionOptionableRXRXRecursion Pharmaceuticals400529.91 million485.23 millionOptionableSDGRSchrodinger79073.82 million66.37 millionOptionableSMMTSummit Therapeutics110776.16 million128.07 millionOptionableSMMT, SDGR, RXRX, and HIMS HeadlinesRecent News About These CompaniesSummit Therapeutics PLC $SMMT Stock Holdings Decreased by Vanguard Group Inc.May 11, 2026 | marketbeat.comWall Street Zen Upgrades Summit Therapeutics (NASDAQ:SMMT) to "Hold"May 10, 2026 | americanbankingnews.comSummit Therapeutics (NASDAQ:SMMT) Upgraded at Wall Street ZenMay 10, 2026 | marketbeat.comQ2 EPS Estimate for Summit Therapeutics Boosted by AnalystMay 8, 2026 | marketbeat.comQ2 Earnings Forecast for SMMT Issued By HC WainwrightMay 7, 2026 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Given New $23.00 Price Target at HC WainwrightMay 5, 2026 | americanbankingnews.comSMMT Q1 Loss Narrower Than Expected, Stock Down on Ivonescimab SetbackMay 4, 2026 | zacks.comSummit Therapeutics: More Uncertainty Heading Into The ASCO PlenaryMay 4, 2026 | seekingalpha.comBuy These 3 Clinical-Stage Biotechs Under $30 With Solid Cash RunwaysMay 4, 2026 | 247wallst.comSummit Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesMay 4, 2026 | globenewswire.comHC Wainwright Issues Pessimistic Forecast for Summit Therapeutics (NASDAQ:SMMT) Stock PriceMay 4, 2026 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Adagene (ADAG) and Summit Therapeutics (SMMT)May 3, 2026 | theglobeandmail.comSummit Therapeutics (SMMT) Receives a Rating Update from a Top AnalystMay 3, 2026 | theglobeandmail.comSMMT stock plunges on wider Q1 loss, lung cancer clinical trial updateMay 2, 2026 | msn.comSummit Therapeutics (NASDAQ:SMMT) Issues Earnings ResultsMay 2, 2026 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Raised to "Sell" at Wall Street ZenMay 2, 2026 | marketbeat.comSummit Therapeutics Shock Move Hits Nasdaq FuturesMay 1, 2026 | kalkinemedia.comKSummit Therapeutics falls after update on Akeso-partnered lung cancer trialMay 1, 2026 | msn.comSummit Therapeutics (NASDAQ:SMMT) Shares Gap Down - Time to Sell?May 1, 2026 | marketbeat.comSummit Therapeutics PLC $SMMT Shares Sold by Pictet Asset Management Holding SAMay 1, 2026 | marketbeat.comSummit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026April 30, 2026 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026What the FDA's Latest Proposal Means for Lilly, Novo, and HimsBy Leo Miller | May 7, 2026Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in FocusBy Jessica Mitacek | May 8, 2026Amazon Takes a Bite Out of Hims: What Its GLP-1 Entrance MeansBy Leo Miller | April 28, 2026Hims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?By Jessica Mitacek | May 12, 2026SMMT, SDGR, RXRX, and HIMS Company DescriptionsHims & Hers Health NYSE:HIMS$24.23 +0.09 (+0.39%) Closing price 05/14/2026 03:59 PM EasternExtended Trading$24.22 -0.01 (-0.03%) As of 05/14/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.Recursion Pharmaceuticals NASDAQ:RXRX$3.04 -0.01 (-0.33%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$3.06 +0.02 (+0.56%) As of 05/14/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.Schrodinger NASDAQ:SDGR$12.62 -0.13 (-1.02%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$12.86 +0.24 (+1.89%) As of 05/14/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.Summit Therapeutics NASDAQ:SMMT$18.14 -0.65 (-3.46%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$18.15 +0.01 (+0.06%) As of 05/14/2026 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas YETI Rallies After Earnings Beat and Raised Outlook Cisco’s Vertical Rally May Still Be in the Early Innings Dividend Growth or High Yield: The Income Investor's Bet Nebius Upside Expands as AI Feedback Loop Intensifies Oklo Stock Could Be Ready for Another Massive Run Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell Qualcomm Stock Doubles: New Era? Or Another False Start? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
